In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models
Neutralizing antibody titres have been shown to correlate with immune protection against COVID-19 and can be used to estimate vaccine effectiveness. Numerous studies have explored the relationship between neutralizing antibodies and protection. However, there remains a lack of quantitative data dire...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2025.2459140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849719437092978688 |
|---|---|
| author | Peilan Wei Ruoxi Cai Lu Zhang Jingjun Zhang Zhaoyong Zhang Airu Zhu Hai Li Zhen Zhuang Lan Chen Jiantao Chen Yuting Zhang Xinyi Xiong Bin Qu Jianfen Zhuo Tian Tang Yuanyuan Zhang Lei Chen Qier Zhong Zhiwei Lin Xindan Xing Fang Li Qingtao Hu Jun Dai Yongxia Shi Jingxian Zhao Jincun Zhao Yanqun Wang |
| author_facet | Peilan Wei Ruoxi Cai Lu Zhang Jingjun Zhang Zhaoyong Zhang Airu Zhu Hai Li Zhen Zhuang Lan Chen Jiantao Chen Yuting Zhang Xinyi Xiong Bin Qu Jianfen Zhuo Tian Tang Yuanyuan Zhang Lei Chen Qier Zhong Zhiwei Lin Xindan Xing Fang Li Qingtao Hu Jun Dai Yongxia Shi Jingxian Zhao Jincun Zhao Yanqun Wang |
| author_sort | Peilan Wei |
| collection | DOAJ |
| description | Neutralizing antibody titres have been shown to correlate with immune protection against COVID-19 and can be used to estimate vaccine effectiveness. Numerous studies have explored the relationship between neutralizing antibodies and protection. However, there remains a lack of quantitative data directly assessing the minimum effective protective neutralizing antibody titre in in vivo. In this study, we utilized eight cohorts of participants with diverse immune backgrounds for evaluation of protective antibody response. To precisely assess the lower threshold of neutralizing antibody titres required for effective protection against SARS-CoV-2 infections, we employed plasma adoptive transfer from different cohorts into mice. This study demonstrated that neutralizing titres in the plasma of recipient mice correlated well with those in human donors, and a positive linear correlation was observed between the human and mouse recipients of transferred plasma neutralizing titre. A pseudotyped virus neutralizing titres greater than 7 was identified as the minimum threshold necessary to reduce viral titres in infected mice, establishing a crucial baseline for effective protection. Furthermore, despite the variability in immune backgrounds, these diverse cohorts’ plasma exhibited a similar neutralizing antibody threshold necessary for protection. This finding has significant implications for vaccine design and the assessment of immune competence. |
| format | Article |
| id | doaj-art-83135ee5673b4dada0bb7d0a4df31991 |
| institution | DOAJ |
| issn | 2222-1751 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-83135ee5673b4dada0bb7d0a4df319912025-08-20T03:12:09ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512025-12-0114110.1080/22221751.2025.2459140In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse modelsPeilan Wei0Ruoxi Cai1Lu Zhang2Jingjun Zhang3Zhaoyong Zhang4Airu Zhu5Hai Li6Zhen Zhuang7Lan Chen8Jiantao Chen9Yuting Zhang10Xinyi Xiong11Bin Qu12Jianfen Zhuo13Tian Tang14Yuanyuan Zhang15Lei Chen16Qier Zhong17Zhiwei Lin18Xindan Xing19Fang Li20Qingtao Hu21Jun Dai22Yongxia Shi23Jingxian Zhao24Jincun Zhao25Yanqun Wang26State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaHealth and Quarantine Laboratory, State Key Laboratory of Respiratory Disease of Guangzhou Customs District Technology Center, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaNHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaShanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of ChinaShanghai Institute for Advanced Immunochemical Studies, School of Life Science and Technology, ShanghaiTech University, Shanghai, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaGMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, People’s Republic of ChinaHealth and Quarantine Laboratory, State Key Laboratory of Respiratory Disease of Guangzhou Customs District Technology Center, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaHealth and Quarantine Laboratory, State Key Laboratory of Respiratory Disease of Guangzhou Customs District Technology Center, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of ChinaNeutralizing antibody titres have been shown to correlate with immune protection against COVID-19 and can be used to estimate vaccine effectiveness. Numerous studies have explored the relationship between neutralizing antibodies and protection. However, there remains a lack of quantitative data directly assessing the minimum effective protective neutralizing antibody titre in in vivo. In this study, we utilized eight cohorts of participants with diverse immune backgrounds for evaluation of protective antibody response. To precisely assess the lower threshold of neutralizing antibody titres required for effective protection against SARS-CoV-2 infections, we employed plasma adoptive transfer from different cohorts into mice. This study demonstrated that neutralizing titres in the plasma of recipient mice correlated well with those in human donors, and a positive linear correlation was observed between the human and mouse recipients of transferred plasma neutralizing titre. A pseudotyped virus neutralizing titres greater than 7 was identified as the minimum threshold necessary to reduce viral titres in infected mice, establishing a crucial baseline for effective protection. Furthermore, despite the variability in immune backgrounds, these diverse cohorts’ plasma exhibited a similar neutralizing antibody threshold necessary for protection. This finding has significant implications for vaccine design and the assessment of immune competence.https://www.tandfonline.com/doi/10.1080/22221751.2025.2459140SARS-CoV-2protective antibodythresholdneutralizing titremouse modelin vivo |
| spellingShingle | Peilan Wei Ruoxi Cai Lu Zhang Jingjun Zhang Zhaoyong Zhang Airu Zhu Hai Li Zhen Zhuang Lan Chen Jiantao Chen Yuting Zhang Xinyi Xiong Bin Qu Jianfen Zhuo Tian Tang Yuanyuan Zhang Lei Chen Qier Zhong Zhiwei Lin Xindan Xing Fang Li Qingtao Hu Jun Dai Yongxia Shi Jingxian Zhao Jincun Zhao Yanqun Wang In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models Emerging Microbes and Infections SARS-CoV-2 protective antibody threshold neutralizing titre mouse model in vivo |
| title | In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models |
| title_full | In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models |
| title_fullStr | In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models |
| title_full_unstemmed | In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models |
| title_short | In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models |
| title_sort | in vivo determination of protective antibody thresholds for sars cov 2 variants using mouse models |
| topic | SARS-CoV-2 protective antibody threshold neutralizing titre mouse model in vivo |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2025.2459140 |
| work_keys_str_mv | AT peilanwei invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT ruoxicai invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT luzhang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT jingjunzhang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT zhaoyongzhang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT airuzhu invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT haili invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT zhenzhuang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT lanchen invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT jiantaochen invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT yutingzhang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT xinyixiong invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT binqu invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT jianfenzhuo invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT tiantang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT yuanyuanzhang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT leichen invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT qierzhong invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT zhiweilin invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT xindanxing invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT fangli invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT qingtaohu invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT jundai invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT yongxiashi invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT jingxianzhao invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT jincunzhao invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels AT yanqunwang invivodeterminationofprotectiveantibodythresholdsforsarscov2variantsusingmousemodels |